Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.
Postmenopausal women who are younger, have higher levels of the bone turnover marker sCTX, and did not receive zoledronate prior to initiating denosumab treatment have an elevated risk of significant bone mineral density (BMD) loss 1 year after denosumab discontinuation, according to results of the ReoLaus* Bone Project presented at EULAR 2019.
Teriparatide appears to produce significant reductions in the incidence of fractures in the period beyond 6 months after treatment initiation, with the benefit consistently observed across important patient subgroups, according to data from four real-world studies.
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Denosumab yields increases in bone mineral density (BMD) in patients with glucocorticoid-induced osteoporosis (GIOP), and this benefit is not influenced by prior antiosteoporotic treatment, as shown in a study.
Patients with systemic sclerosis (SSc) or rheumatoid arthritis show lower trabecular bone score and bone mineral density compared with healthy individuals, according to a study. Moreover, SSc patients appear to have poorer bone quality with markedly altered microvasculature.
The monoclonal antibody denosumab demonstrates potent antiresorptive effect in the treatment of osteoporosis, conferring benefit for fracture risk and averting bone loss in select oncological situations. The drug must be used without interruption to prevent a rebound effect, according to Dr Tai-Pang Ip, a consultant endocrinologist from Hong Kong who spoke at AFOS 2017 held in Kuala Lumpur, Malaysia.
An initial strategy of 1-year romosozumab followed by alendronate is superior over alendronate alone in reducing new vertebral fractures in postmenopausal women with osteoporosis at high risk for fracture, according to the ARCH* study.
Women who temporarily or permanently stop taking bisphosphonates (drug holiday) for an extended period of time may have an increased risk of hip fractures, findings from a recent population-based study revealed.
The coexistence of fibromyalgia in patients with axial spondyloarthritis (axSpA) exerts a negative effect on response to tumour necrosis factor blocker, according to a study. This effect appears to be associated with the self-reported instruments used in fibromyalgia evaluation rather than a different treatment effect of the agent in this population.